AnaptysBio Inc

Research AnaptysBio Inc (ANAB) on Bullrun: market cap USD 1.92B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerANAB
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.92B
• Financial periodFY2025
• RevenueUSD 234.60M
• Revenue growth157.0%
• Net income-USD 13.23M
• Free cash flowUSD 19.61M

Valuation Snapshot

latest market cap is USD 1.92B.

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis;

Frequently asked questions

What is AnaptysBio Inc's market cap?

AnaptysBio Inc's market capitalization is USD 1.92B.

What does AnaptysBio Inc do?

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.